Evidence map›Paper›PMID 21509503›Full record

ArticlePsychopharmacology2011

Inhibition of phosphodiesterase-4 decreases ethanol intake in mice.

Wei Hu, Tina Lu, Alan Chen, Ying Huang, Rolf Hansen, L Judson Chandler, Han-Ting Zhang

Abstract readComparative Study
In one paragraph

Article in Psychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 77 citations in OpenAlex.

  1. Trial
  2. Global deletion ofbioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. PET imaging in rat brain shows opposite effects of acute and chronic alcohol exposure on phosphodiesterase-4B, an indirect biomarker of cAMP activity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  8. Article
  9. Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wei HuDepartment of Behavioral Medicine and Psychiatry, West Virginia University Health Sciences Center, 1 Medical Center Drive, Morgantown, WV 26506-9137, USA.
Tina Lu
Alan Chen
Ying Huang
Rolf Hansen
L Judson Chandler
Han-Ting Zhang
West Virginia University · USMedical University of South Carolina · US

Funding

ETHANOL AND NITRIC OXIDE FORMATION IN BRAINR01AA010983 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI CHANDLER, L JUDSON · 2001 to 2013
$3.5M
Phosphodiesterease-4 (PDE4) as a Novel Target to Reduce Ethanol ConsumptionR21AA020042 · NIAAA · WEST VIRGINIA UNIVERSITY · PI ZHANG, HAN-TING · 2011 to 2012
$389k
NIAAA NIH HHS R01 AA010983NIAAA NIH HHS R21 AA020042
6 · The paper itself

Abstract

rationaleCyclic AMP (cAMP)-protein kinase A signaling has been implicated in the regulation of ethanol consumption. Phosphodiesterase-4 (PDE4) specifically hydrolyzes cAMP and plays a critical role in controlling intracellular cAMP levels in the brain. However, the role of PDE4 in ethanol consumption remains unknown.

objectiveThe objective of this study is to examine whether PDE4 was involved in regulating ethanol intake.

methodsThe two-bottle choice paradigm was used to assess intake of ethanol, sucrose, and quinine in C57BL/6J mice treated with the selective PDE4 inhibitor rolipram or Ro 20-1724; locomotor activity was also monitored using the open-field test in mice treated with rolipram.

resultsAdministration (i.p.) of either rolipram (0.25 and 0.5 mg/kg) or Ro 20-1724 (10 mg/kg) reduced ethanol intake and preference by 60-80%, but did not alter total fluid intake. In contrast, rolipram even at the higher dose of 0.5 mg/kg was not able to affect intake of sucrose or quinine, alcohol-induced sedation, or blood ethanol elimination. At 0.5 mg/kg, rolipram did decrease locomotor activity, but the effect only lasted for approximately 40 min, which did not likely affect behavior of ethanol drinking.

conclusionsThese results suggest that PDE4 is a novel target for drugs that reduce ethanol intake; PDE4 inhibitors may be used for treatment of alcohol dependence.

Indexed as

4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinoneAlcohol DrinkingAnimalsBrainCentral Nervous System DepressantsCyclic Nucleotide Phosphodiesterases, Type 4Dose-Response Relationship, DrugEthanolMaleMiceMice, Inbred C57BLMotor ActivityPhosphodiesterase 4 InhibitorsPhosphodiesterase InhibitorsQuinineRolipram4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinoneCentral Nervous System DepressantsCyclic Nucleotide Phosphodiesterases, Type 4EthanolPhosphodiesterase 4 InhibitorsPhosphodiesterase InhibitorsQuinineRolipramSucrose

Identifiers

PMID21509503
PMCPMC4210373
OpenAlexW2125899972

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.